Comparing low and high dose sirolimus with prednisolone for KHE with KMP
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether a low dose or a high dose of sirolimus (a drug that stops abnormal cell growth) combined with prednisolone (a steroid) works better for children with a rare, aggressive vascular tumor called KHE that also causes low blood platelets (KMP). The goal is to find the safest and most effective dose to help shrink the tumor and improve blood counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 0 and 18 years old.
- Your child must have a confirmed diagnosis of a progressive, unresectable KHE (a type of vascular tumor) that is also causing low blood platelets (KMP).
- Your child must not be currently needing treatment with corticosteroids for health problems caused by the KHE.
- Your child's liver, kidney, and bone marrow function must be in a healthy range based on blood tests.
- Your child must not have a serious infection requiring IV antibiotics, a known immune problem, or a history of cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at different ways to stop taking sirolimus for children with KHE, a rare blood vessel tumor. It helps find the best plan to prevent the tumor from coming back after treatment.
This trial tests different doses of sirolimus (a medication that slows cell growth) to find the best dose for treating cystic lymphatic malformations in children. It may help shrink the abnormal fluid-filled growths and improve symptoms.
This trial studies how the medicine sirolimus affects children’s response to routine vaccines during treatment for kaposiform hemangioendothelioma (KHE). It compares vaccinated KHE patients taking sirolimus with healthy children getting the same vaccines.
This trial tests whether the drug sirolimus (rapamycin) can help people with dilated cardiomyopathy who also have a specific virus (KSHV) in their blood. It aims to see if sirolimus can improve heart function.
This trial tests a new form of sirolimus (a targeted therapy) for people with a rare cancer called EHE that is growing or causing symptoms. If you have EHE that can't be removed with surgery and needs treatment, this study may be an option.
This trial is studying a drug called nab-sirolimus for people with a rare type of vascular tumor called epithelioid hemangioendothelioma (EHE) that is growing or causing symptoms. The goal is to see if the drug can help control the tumor.
Hear when a new Kaposiform Hemangioendothelioma (KHE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.